S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
AVIR · Atea Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Atea Pharmaceuticals Inc (AVIR)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$4.07
-0.39
(-8.74%)
● At close: October 21 at 4:00:00 PM EDT
$4.08
+0.00
(+0.00%)
After-Hours:
4:01:33 PM EDT
DAY'S RANGE
$4.07
$4.05
$4.45
52-WEEK RANGE
$4.07
$2.87
$6.45
What's happening
- AVIR is down 8.74% today, trading at $4.07. — Live quote
- Volume today (42,190) is well below its 3-month average of 319,700. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 15 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.41 actual vs. $-0.57 estimated (+28.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 4
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AVIR
+25.07%
vs S&P 500
+12.29%
1-YEAR RETURN
AVIR
+38.66%
vs S&P 500
+24.10%
6-MONTH RETURN
AVIR
-21.67%
3-MONTH RETURN
AVIR
-8.32%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.41
Est. $-0.57
BEAT +28.2%
2026-04-26 (Q1 2026)
$-0.57
Est. $-0.60
BEAT +5.3%
2026-01-26 (Q4 2025)
$-0.57
Est. $-0.54
MISS -5.4%
2025-10-26 (Q3 2025)
$-0.53
Est. $-0.45
MISS -18.1%
Valuation Measures & Ratios
Enterprise Value4$281.6M
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)1.02
Price / Book71.82
EV4 / Revenue0.80
EV4 / EBITDA9.20
Profit Margin34.46%
Operating Margin39.41%
Return on Equity (ROE8)-64.25%
Return on Assets (ROA9)-57.12%
Avg Volume (3M)319,700
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $373.5M | $428.5M | $230.1M | $303.2M | $257.0M |
| P/E | -2.37 | -2.70 | -1.59 | -2.12 | -1.52 |
| Price/Book | 1.83 | 1.83 | 0.73 | 0.83 | 0.63 |
| ROE | -77.19% | -68.00% | -45.80% | -39.27% | -41.14% |
| ROA | -67.84% | -59.50% | -42.17% | -36.54% | -38.44% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,886,499
Change from Prior Settlement+3.36%
% of Float—
Days to Cover (Short Ratio)25.86
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Net profit margin is 34.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is +38.7%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 10-Q, filed 2026-08-12; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AVIR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$35.1M | -$48.0M | -$45.6M | -$41.3M | -$39.0M | -$37.2M | -$46.9M | -$69.8M |
| Net income | -$32.9M | -$45.4M | -$42.0M | -$37.2M | -$34.3M | -$31.2M | -$40.5M | -$63.2M |
| EPS (diluted) | $-0.41 | $-0.57 | $-0.53 | $-0.44 | $-0.40 | $-0.37 | $-0.48 | $-0.75 |
| EPS (basic) | $-0.41 | $-0.57 | $-0.53 | $-0.44 | $-0.40 | $-0.37 | $-0.48 | $-0.75 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $232.3M | $267.1M | $315.2M | $343.0M | $391.6M | $440.0M | $464.7M | $491.0M |
| Total liabilities | — | — | $39.8M | $27.2M | $27.2M | $28.9M | $25.8M | $32.4M |
| Stockholders' equity | $204.2M | $233.7M | $275.4M | $315.8M | $364.4M | $411.1M | $438.9M | $458.5M |
| Total current assets | $228.7M | $263.2M | $311.0M | $336.1M | $385.6M | $433.7M | $462.4M | $486.9M |
| Total current liabilities | $28.1M | $33.4M | $39.8M | $20.2M | $20.1M | $21.7M | $18.6M | $25.2M |
| Cash & equivalents | $76.5M | $79.3M | $95.7M | $77.3M | $87.7M | $119.4M | $64.7M | $98.5M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $249.0K | $353.0K | $457.0K | $561.0K | $665.0K | $769.0K | $873.0K | $977.0K |
| Other non-current assets | $3.0M | $3.0M | $3.1M | $5.5M | $4.4M | $4.4M | $197.0K | $1.7M |
| Accounts payable | $10.1M | $9.4M | $12.9M | $3.5M | $8.8M | $7.4M | $4.5M | $5.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $80.0K | $80.0K | $78.0K | $78.0K | $81.0K | $85.0K | $84.0K | $84.0K |
| Retained earnings | -$600.9M | -$568.0M | -$522.6M | -$477.7M | -$435.7M | -$398.5M | -$364.2M | -$330.7M |
| Accumulated other comprehensive income (loss) | -$96.0K | -$97.0K | $174.0K | $238.0K | $37.0K | $118.0K | $233.0K | $641.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$37.1M | -$46.4M | -$28.2M | -$40.4M | -$32.9M | -$30.6M | -$30.4M | -$23.0M |
| Investing cash flow | $34.3M | $29.7M | $46.6M | $41.3M | $15.3M | $85.6M | -$3.4M | -$122.0M |
| Financing cash flow | $0 | $257.0K | $0 | -$11.3M | -$14.1M | -$347.0K | $0 | $117.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | $3.4M | $3.7M | $4.6M | $4.5M | $4.7M | $7.0M | $14.3M | $12.2M |
| Deferred income taxes | — | — | -$6.4M | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | $612.0K | -$3.5M | $9.4M | -$5.3M | $1.5M | $2.9M | -$1.3M | $315.0K |
| Purchases of investments | $33.8M | $74.5M | $43.8M | $14.8M | $100.7M | $122.6M | $58.5M | $228.2M |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | $0 | $11.4M | $14.1M | — | $0 | — |
| Tax withholding on stock comp | $0 | $746.0K | $0 | $0 | $0 | $485.0K | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M |
| Net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M | $121.2M |
| EPS (diluted) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 |
| EPS (basic) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.46 |
| Operating margin | — | — | — | — | $39 |
| Net margin | — | — | — | — | $34 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
| Stockholders' equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
| Total current assets | $311.0M | $462.4M | $590.5M | $660.9M | $772.4M |
| Total current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M |
| Cash & equivalents | $95.7M | $64.7M | $143.8M | $188.5M | $764.4M |
| Property, plant & equipment | $457.0K | $873.0K | $1.3M | $1.7M | $23.0K |
| Other non-current assets | $3.1M | $197.0K | $1.4M | $1.5M | $466.0K |
| Accounts payable | $12.9M | $4.5M | $4.3M | $2.6M | $4.5M |
| Deferred revenue (current) | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | $5.9M |
| Common stock & paid-in capital | $78.0K | $84.0K | $83.0K | $83.0K | $83.0K |
| Retained earnings | -$522.6M | -$364.2M | -$195.8M | -$59.9M | $56.0M |
| Accumulated other comprehensive income (loss) | $174.0K | $233.0K | $207.0K | -$684.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M |
| Investing cash flow | $188.8M | $56.1M | $40.3M | -$455.4M | -$4.0K |
| Financing cash flow | -$25.7M | $267.0K | $257.0K | $370.0K | $1.5M |
| Free cash flow | — | — | — | -$122.9M | -$87.0M |
| Capital expenditures | — | — | — | $1.9M | $4.0K |
| Share-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M |
| Deferred income taxes | -$6.4M | $0 | — | — | — |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | $8.5M | $206.0K | $1.7M | -$2.0M | $10.3M |
| Purchases of investments | $281.9M | $461.2M | $562.4M | $545.4M | — |
| Share repurchases | $25.5M | $0 | — | — | — |
| Tax withholding on stock comp | $485.0K | $0 | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AVIR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-31 to 2026-06-18
Recent transactions
- Most recent: Lucidi Bruno (Reporting person) — Option exercise of 29,600 shares on 2026-06-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lucidi Bruno | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| BERGER FRANKLIN M | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| DUNCAN BARBARA GAYLE | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| Polsky Bruce | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| Murphy Polly A. | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| Adams Jerome M. | Reporting person | Option exercise | 2026-06-18 | 29,600 |
| Corcoran Andrea | See Remarks | Option exercise | 2026-03-11 | 60,000 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | Option exercise | 2026-02-03 | 300,000 |
| Horga Maria Arantxa | Chief Medical Officer | Option exercise | 2026-01-31 | 51,283 |
| Vavricka John | Chief Commercial Officer | Option exercise | 2026-01-31 | 42,083 |
| Hammond Janet MJ | Chief Development Officer | Option exercise | 2026-01-31 | 58,050 |
| Foster Wayne | EVP, Chief Accounting Officer | Option exercise | 2026-01-31 | 41,333 |
| Duncan Barbara Gayle | Reporting person | Option exercise | 2025-06-20 | 29,600 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-18 | Lucidi Bruno | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-06-18 | BERGER FRANKLIN M | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-06-18 | Polsky Bruce | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-06-18 | Murphy Polly A. | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-06-18 | Adams Jerome M. | Reporting person | Option exercise | 29,600 | $0.00 |
| 2026-03-11 | Corcoran Andrea | See Remarks | Option exercise | 60,000 | $1.24 |
| 2026-02-03 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Option exercise | 300,000 | $1.24 |
| 2026-01-31 | Horga Maria Arantxa | Chief Medical Officer | Option exercise | 51,283 | — |
| 2026-01-31 | Horga Maria Arantxa | Chief Medical Officer | Tax withholding | 16,073 | $4.24 |
| 2026-01-31 | Vavricka John | Chief Commercial Officer | Option exercise | 42,083 | — |
| 2026-01-31 | Vavricka John | Chief Commercial Officer | Tax withholding | 11,570 | $4.24 |
| 2026-01-31 | Hammond Janet MJ | Chief Development Officer | Option exercise | 58,050 | — |
| 2026-01-31 | Hammond Janet MJ | Chief Development Officer | Tax withholding | 14,136 | $4.24 |
| 2026-01-31 | Corcoran Andrea | See Remarks | Option exercise | 54,866 | — |
| 2026-01-31 | Corcoran Andrea | See Remarks | Tax withholding | 16,104 | $4.24 |
| 2026-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Option exercise | 272,983 | — |
| 2026-01-31 | Sommadossi Jean-Pierre | President, CEO, and Chairman | Tax withholding | 106,093 | $4.24 |
| 2026-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Option exercise | 41,333 | — |
| 2026-01-31 | Foster Wayne | EVP, Chief Accounting Officer | Tax withholding | 12,132 | $4.24 |
| 2025-06-20 | Murphy Polly A. | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-06-20 | Duncan Barbara Gayle | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-06-20 | BERGER FRANKLIN M | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-06-20 | Polsky Bruce | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-06-20 | Adams Jerome M. | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-06-20 | Lucidi Bruno | Reporting person | Option exercise | 29,600 | $0.00 |
| 2025-05-18 | Murphy Polly A. | Reporting person | Open market purchase | 6,100 | $4.17 |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Option exercise | 46,800 | — |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Grant / award | 11,250 | — |
| 2025-01-31 | Hammond Janet MJ | Chief Development Officer | Tax withholding | 14,134 | $3.06 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:52 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-12 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-12 | 8-K | 2026-08-12 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-22 | 8-K | 2026-06-18 | View on SEC.gov → |
| 2026-05-20 | 4 | 2026-05-18 | View on SEC.gov → |
Recent news
Headlines about AVIR (Atea Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
AVIR271217C00005000 interactive stock chart | AVIR Dec 2027 5.000 call stock
Yahoo Finance Australia · 2026-10-16 -
AVIR Dec 2027 5.000 call (AVIR271217C00005000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-15 -
Atea Pharmaceuticals, Inc. (AVIR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · 2026-09-15 -
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance · 2026-09-08 -
Atea (AVIR) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-19 -
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch
Seeking Alpha · 2026-08-12 -
Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-12 -
Atea Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha · 2026-08-12
No headlines in this category right now — try “All”.